Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Numerous reports have described Toll-like receptor (TLR) expression in the tumor microenvironment as it relates to cancer progression, as well as their involvement in inflammation. While TLRs mediate immune surveillance, clinical studies have associated TLR expression in the tumor with poor patient survival, indicating that TLR expression may affect cancer treatment and survival. This review will examine mechanisms in which TLR activation upregulates protumorigenic pathways, including the induction of inducible nitric oxide synthase (iNOS2) and COX2, which in turn increase TLR expression and promote a feed-forward loop leading to tumor progression and the development of more aggressive tumor phenotypes. These propagating loops involve cancer cell, stroma, and/or immune cell TLR expression. Because of abundant TLR expression in many human tumors, several TLR agonists are now in clinical and preclinical trials and some have shown enhanced efficacy when used as adjuvant with radiation, chemotherapy, or cancer vaccines. These findings suggest that TLR expression influences cancer biology and therapeutic response, which may involve specific interactions within the tumor microenvironment, including mediators of inflammation such as nitric oxide and the arachidonic acid signaling pathways. Clin Cancer Res; 19(6); 1340–6. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667
Thomas, D. D., Espey, M. G., Ridnour, L. A., Hofseth, L. J., Mancardi, D., Harris, C. C., & Wink, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400453101 · Cited by 289
Self-citationIncreased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients
Glynn, S. A., Boersma, B. J., Dorsey, T. H., Yi, M., Yfantis, H. G., Ridnour, L. A., Martin, D. N., Switzer, C. H., Hudson, R. S., Wink, D. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42059 · Cited by 254
Self-citationSwitzer, C. H., Glynn, S. A., Cheng, R. Y.-S., Ridnour, L. A., Green, J. E., Ambs, S., & Wink, D. A. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0124 · Cited by 141
Self-citationNitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation
Ridnour, L. A., Barasch, K. M., Windhausen, A. N., Dorsey, T. H., Lizardo, M. M., Yfantis, H. G., Lee, D. H., Switzer, C. H., Cheng, R. Y. S., Heinecke, J. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044081 · Cited by 71
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Wu, J.-Y., Huang, T.-W., Hsieh, Y.-T., Wang, Y.-F., Yen, C.-C., Lee, G.-L., Yeh, C.-C., Peng, Y.-J., Kuo, Y.-Y., Wen, H.-T., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.10.023 · Cited by 535
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression
Heinecke, J. L., Ridnour, L. A., Cheng, R. Y. S., Switzer, C. H., Lizardo, M. M., Khanna, C., Glynn, S. A., Hussain, S. P., Young, H. A., Ambs, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401799111 · Cited by 177
Self-citation
Metadata
- Authors
- Ridnour, L. A., Cheng, R. Y. S., Switzer, C. H., Heinecke, J. L., Ambs, S., Glynn, S., Young, H. A., Trinchieri, G., & Wink, D. A.
- Venue
- Clinical Cancer Research
- Published
- 2013-03-14
- Volume
- 19
- Issue
- 6
- Pages
- 1340-1346
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2170307392
- Cited by
- 147
- References
- 6
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0408
- The paper
- Ridnour, L. A., Cheng, R. Y. S., Switzer, C. H., Heinecke, J. L., Ambs, S., Glynn, S., Young, H. A., Trinchieri, G., & Wink, D. A. (2013). Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0408
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.